The Webinar Series will take place bi-weekly on: Thursdays

12 pm noon (EDT/EST)

9 am (PT), 5 pm (UCT/GMT), 6 pm (CET/CEST)

We will use a single Zoom webinar registration for the upcoming seminars:

Some seminars might be recorded and accessible for a limited time.


Upcoming Speakers

Ning Zheng Photo.jpeg

Host: Sagar Koduri
May 26th, 2022 
Ning Zheng
University of Washington
Define Molecular Glues with Unifying Themes.

Dr. Ning Zheng obtained his PhD from University of Texas Southwestern Medical Center in 1997 after he attended Fudan University in Shanghai, China. He did his postdoctoral studies at Memorial Sloan-Kettering Cancer Center and joined the faculty at the Department of Pharmacology in the University of Washington in 2002. He is currently Howard Hughes Medical Institute Investigator and an AAAS Fellow. His current research focuses on structural and functional analyses of ubiquitin ligases, their roles in plant hormone signaling, and their potential in mediating targeted protein degradation for novel therapeutic drug development.

Photo Sep 2021.png

Host: Breanna Zerfas
June 9th, 2022 
Lyn Jones
Center for Protein Degradation, Dana-Farber Cancer Institute
Covalent modulation of cereblon using sulfonyl exchange chemistry.

Lyn Jones received his PhD in synthetic organic chemistry from the University of Nottingham and completed postdoctoral research at The Scripps Research Institute (La Jolla, California) in chemical biology. He joined Pfizer (Sandwich, UK) as a medicinal chemistry team leader, eventually becoming Director of Chemical Biology and Lead Discovery Technologies. He transferred to Pfizer Cambridge, MA to become Head of Rare Disease Chemistry and Head of Chemical Biology. He then joined Jnana Therapeutics as Head of Chemistry and Chemical Biology, before moving to his current role as Director of the Center for Protein Degradation at the Dana-Farber Cancer Institute in Boston. He is an elected Fellow of the American Association for the Advancement of Science, the Royal Society of Chemistry, the Royal Society of Biology, and the Linnean Society. His research interests include the use of chemoproteomics and chemogenomics to advance new therapeutic modalities.